Author + information
- Sunao Nakamura,
- Hisao Ogawa,
- Hans Yeo,
- Wasan Udayachalerm,
- Damras Tresukosol and
- Sudaratana Tansuphaswadikul
The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES–R/Endeavor Resolute), BiolimusA9 (BES), EPC capture (ECS) and Everolimus–eluting stent (EES) on the outcome of patients with chronic total occlusion (CTO).
A prospective analysis of 1576 patients with 1738 CTOs (396 SES, 526 PES, 219 ZES–R, 209 BES, 148 ECS, 240 EES) in six high volume Asian centers after successful recanalization of CTO was performed. The study endpoints were 30 days and 12 and 36 months major adverse cardiac events (MACE) and target lesion revascularization (TLR).
See table for clinical Results.
The use of drug–eluting stents in patients with CTO was safe with low acute complication. Patients treated with 2nd generation DES such as ZES–R, BES and EES showed lesser rate of restenosis compared with 1st generation drug–eluting stents.
|Number of patients/lesions||365/396||482/526||199/219||188/209||123/148||219/240|
|MACE at 30 days (%)||0.5||0.6||0.5||0||0.8||0|
|Proximal RD (mean: mm)||2.86||2.80||2.85||2.84||2.92||2.87|
|MLD at baseline (mean: mm)||2.65||2.54||2.60||2.78||2.62||2.67|
|12 months MLD (mean: mm)||2.50||2.30||2.49||2.66||2.10||2.58|
|36 months MLD (mean: mm)||2.20||2.02||2.35||2.45||1.89||2.40|
Poster Sessions, Expo North
Saturday, March 09, 2013, 3:45 p.m.–4:30 p.m.
Session Title: Chronic Total Occlusions
Abstract Category: 44. TCT@ACC–i2: Coronary Intervention, CTO
Presentation Number: 2103–238
- 2013 American College of Cardiology Foundation